Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1428 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.000853 | uM | 7444.091 | 0.9711 | 0.9342 | 0.8764 | |
| HCC1428 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.00427 | uM | 7444.091 | 0.9809 | 0.9564 | 0.8764 | |
| HCC1428 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.0213 | uM | 7444.091 | 1.0098 | 1.0225 | 0.8764 | |
| HCC1428 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.107 | uM | 7444.091 | 1.0140 | 1.0319 | 0.8764 | |
| HCC1428 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.533 | uM | 7444.091 | 0.9949 | 0.9884 | 0.8764 | |
| HCC1428 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 2.67 | uM | 7444.091 | 0.9765 | 0.9465 | 0.8764 | |
| HCC1428 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 13.3 | uM | 7444.091 | 0.8167 | 0.5873 | 0.8764 | |
| HCC1428 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 66.7 | uM | 7444.091 | 0.6736 | 0.2742 | 0.8764 | |
| HCC1569 | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 0.000171 | uM | 7447.09 | 0.9517 | 0.9385 | 1.5863 | |
| HCC1569 | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 0.000853 | uM | 7447.09 | 0.9786 | 0.9729 | 1.5863 | |
| HCC1569 | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 0.00427 | uM | 7447.09 | 0.9375 | 0.9203 | 1.5863 | |
| HCC1569 | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 0.0213 | uM | 7447.09 | 0.9425 | 0.9268 | 1.5863 | |
| HCC1569 | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 0.107 | uM | 7447.09 | 0.9032 | 0.8756 | 1.5863 | |
| HCC1569 | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 0.533 | uM | 7447.09 | 0.9595 | 0.9486 | 1.5863 | |
| HCC1569 | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 2.67 | uM | 7447.09 | 0.9072 | 0.8809 | 1.5863 | |
| HCC1569 | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 13.3 | uM | 7447.09 | 0.7252 | 0.6333 | 1.5863 | |
| HCC1569 | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 66.7 | uM | 7447.09 | 0.4615 | 0.2284 | 1.5863 | |
| HCC1569 | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 0.000171 | uM | 7449.091 | 1.0176 | 1.0194 | 1.8158 | |
| HCC1569 | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 0.000853 | uM | 7449.091 | 1.0442 | 1.0483 | 1.8158 | |
| HCC1569 | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 0.00427 | uM | 7449.091 | 0.9817 | 0.9798 | 1.8158 | |
| HCC1569 | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 0.0213 | uM | 7449.091 | 0.9794 | 0.9772 | 1.8158 | |
| HCC1569 | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 0.107 | uM | 7449.091 | 1.0113 | 1.0125 | 1.8158 | |
| HCC1569 | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 0.533 | uM | 7449.091 | 0.9974 | 0.9972 | 1.8158 | |
| HCC1569 | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 2.67 | uM | 7449.091 | 0.9556 | 0.9506 | 1.8158 | |
| HCC1569 | HER2amp | Basal A | Erlotinib | EGFR | ErbB | 13.3 | uM | 7449.091 | 0.6794 | 0.6166 | 1.8158 |